UY29128A1 - Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos - Google Patents

Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos

Info

Publication number
UY29128A1
UY29128A1 UY29128A UY29128A UY29128A1 UY 29128 A1 UY29128 A1 UY 29128A1 UY 29128 A UY29128 A UY 29128A UY 29128 A UY29128 A UY 29128A UY 29128 A1 UY29128 A1 UY 29128A1
Authority
UY
Uruguay
Prior art keywords
methods
compositions
derived
epithopes
proteins derived
Prior art date
Application number
UY29128A
Other languages
English (en)
Inventor
Jacqueline Benson
Mark Cunningham
Jeffrey Luo
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of UY29128A1 publication Critical patent/UY29128A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una proteína derivada de Ig humana, específica de anti-IL-23, ácidos nucleicos aislados, que codifican por lo menos una proteina derivada de Ig anti-IL-23, vectores, células huésped, plantas o animales transgénicos, y los métodos para preparar y usar los mismos, que son útiles como composiciones, métodos y dispositivos terapéuticos y de diagnóstico. La proteína derivada de Ig anti-IL-23 se une preferiblemente a uno o más de los epitopes Seg1, Seg2, y Seg3 de la subunidad p40 de IL-23.
UY29128A 2004-09-24 2005-09-23 Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos UY29128A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61286604P 2004-09-24 2004-09-24
US61683204P 2004-10-07 2004-10-07

Publications (1)

Publication Number Publication Date
UY29128A1 true UY29128A1 (es) 2005-11-30

Family

ID=36119430

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29128A UY29128A1 (es) 2004-09-24 2005-09-23 Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos

Country Status (7)

Country Link
US (2) US7252971B2 (es)
AR (1) AR051444A1 (es)
MY (1) MY141215A (es)
PE (1) PE20060694A1 (es)
TW (1) TWI370136B (es)
UY (1) UY29128A1 (es)
WO (1) WO2006036745A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
DE60328823D1 (de) 2002-10-30 2009-09-24 Genentech Inc Hemmung von il-17 produktion
US20100021455A1 (en) * 2004-12-08 2010-01-28 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
PT2452694T (pt) * 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
EP2116258A1 (en) 2005-09-01 2009-11-11 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
US10716749B2 (en) * 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
KR101210395B1 (ko) * 2005-12-29 2012-12-11 얀센 바이오테크 인코포레이티드 인간 항-ｉｌ-23 항체, 조성물, 방법 및 용도
WO2007147019A2 (en) * 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2008106579A2 (en) * 2007-02-28 2008-09-04 Cedars-Sinai Medical Center The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
CN101668531B (zh) 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US9305137B1 (en) 2007-05-18 2016-04-05 Cedars-Sinai Medical Center Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
WO2008143892A1 (en) * 2007-05-18 2008-11-27 New York University Method of treating tuberculosis with interferons
US9421356B2 (en) * 2007-08-28 2016-08-23 Teikoku Pharma Usa, Inc. Transdermal methods and systems for the delivery of corticosteroid compounds
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
CA2721713C (en) 2008-05-05 2019-07-09 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
ES2444128T3 (es) * 2008-05-13 2014-02-24 Astrazeneca Ab Nueva SAL-554
WO2010017365A1 (en) * 2008-08-06 2010-02-11 University Of Louisville Research Foundation Wax-based emulsion for the treatment of dry eye conditions
WO2010017598A1 (en) * 2008-08-14 2010-02-18 Arana Therapeutics Limited Anti-il-12/il-23 antibodies
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
DK2379497T3 (da) * 2008-12-18 2013-11-25 Novartis Ag Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
MX2011011729A (es) * 2009-05-05 2012-04-10 Novimmune Sa Anticuerpo anti il-17f y metodos de uso de los mismos.
EP2429503A1 (en) * 2009-05-13 2012-03-21 Protein Delivery Solutions, LLC Pharmaceutical system for trans-membrane delivery
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
WO2011109777A1 (en) * 2010-03-05 2011-09-09 Brass Monkey, Inc. System and method for two way communication and controlling content in a web browser
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
CN103108886B (zh) * 2010-07-20 2016-08-24 赛法隆澳大利亚控股有限公司 抗il-23杂二聚体特异性抗体
BR112013028808A2 (pt) 2011-05-10 2016-09-06 Nestec Sa métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada
WO2014113068A1 (en) * 2013-01-18 2014-07-24 Loma Linda University Compositions and methods for diagnosing and treating sepsis
WO2014160883A1 (en) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Treating fibrosis and inflammation by inhibiting tl1a
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CA3044526A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
BR112019011702A2 (pt) 2016-12-14 2019-10-22 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de il-12/il-23 liberado usando um dispositivo ingerível
CA3135012A1 (en) 2017-05-31 2018-12-06 Anjali Jain Methods for assessing mucosal healing in crohn's disease patients
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
AU2661199A (en) 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
DE69942607D1 (de) 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
CA2339047A1 (en) 1998-08-14 2000-02-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CA2366706A1 (en) 1999-03-11 2000-09-14 Schering Corporation Mammalian cytokines; related reagents and methods
US6800460B1 (en) 1999-03-11 2004-10-05 Schering Corporation Mammalian cytokine complexes
JP2002543840A (ja) 1999-05-19 2002-12-24 インサイト・ゲノミックス・インコーポレイテッド 細胞外シグナル伝達分子
HU230679B1 (en) 1999-09-09 2017-08-28 Merck Sharp & Dohme Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
NZ522146A (en) 2000-05-10 2004-10-29 Schering Corp Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
JP2006502114A (ja) * 2002-07-17 2006-01-19 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリクスメタロプロテイナーゼ−１３のアロステリックアルキン阻害薬とセレコキシブまたはバルデコキシブとの組合せ
DE60328823D1 (de) 2002-10-30 2009-09-24 Genentech Inc Hemmung von il-17 produktion
WO2004058178A2 (en) 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
BRPI0408247A (pt) 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
US7501247B2 (en) 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation

Also Published As

Publication number Publication date
WO2006036745A2 (en) 2006-04-06
MY141215A (en) 2010-03-31
TW200626173A (en) 2006-08-01
PE20060694A1 (es) 2006-09-01
TWI370136B (en) 2012-08-11
US20060067936A1 (en) 2006-03-30
AR051444A1 (es) 2007-01-17
WO2006036745A3 (en) 2006-12-28
US7252971B2 (en) 2007-08-07
US20080038831A1 (en) 2008-02-14
US7807471B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
UY29128A1 (es) Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos
EA200701363A1 (ru) Антитела против il-12, эпитопы, композиции, способы и применения
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
EA201070479A1 (ru) Человеческие антиамилоидные антитела, композиции, способы и их применение
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
BRPI0921665A2 (pt) humanizado anti-il-6 anticorpos
CY1121252T1 (el) Anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
CY1115935T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
AR073088A1 (es) Anticuerpos anti-il-13 obtenidos mediante ingenieria composiciones metodos y usos
AR069681A1 (es) Moleculas de union al receptor ox40 humano
WO2006085961A3 (en) Anti-mcp-1 antibodies, compositions, methods and uses
WO2006124451A3 (en) Anti-il-13 antibodies, compositions, methods and uses
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
WO2008048871A3 (en) Cynomolgus il-13 mutein proteins, antibodies, compositions, methods and uses
UY29509A1 (es) Anticuerpos anti-il-6, composiciones, métodos y usos
UY29552A1 (es) Anticuerpos anti-mcp-1, composiciones, métodos y usos
UY33043A (es) Proteinas de enlace de antigenos anti-orai 1 y usos de las mismas
GT200600212A (es) Anticuerpos anti-mcp-1, composiciones, metodos y usos